Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.
about
High accuracy mutation detection in leukemia on a selected panel of cancer genesNSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphomaJanus kinase 3: the controller and the controlledIncreased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation.Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.JAK3: a two-faced player in hematological disordersInhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignanciesJAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.Disease-specific mutations in mature lymphoid neoplasms: recent advances.Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cellsMechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.Development of a high-throughput cell-based reporter assay for screening of JAK3 inhibitors.Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.Regulatory T cells control the CD8 adaptive immune response at the time of ductal obstruction in experimental biliary atresia.A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling.Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
P2860
Q28728910-88BCDFA7-F30C-4850-84B6-8C30D3985515Q33530722-18DDE672-1EA9-4C80-B778-51A84B74643BQ34025763-F38E636E-8E57-4329-A5BD-A16584538912Q34648812-62ED0E40-562D-4C8B-AA9A-AA272F5926D6Q35346411-D26A19F3-BE61-44CC-8FB8-4675EDBFF58AQ35770946-959B6E24-3B44-4427-90A9-F966C804D526Q35780831-BD1E50B5-E5F9-4619-9C34-CE93837EADA2Q35842064-14B55B56-26EC-4B9F-8E72-54DC6AFC53D9Q35884253-418FA8A9-D755-4F31-8BB8-2FAA2FE4DBA4Q37258222-A8672EA7-DF60-4E14-93BA-F5EC10DFE819Q37595688-C6F04BF0-EAD3-4676-BF14-8DBFD895335BQ37695012-A952B7EB-6591-430C-A956-2AE9DE91AA9BQ37808703-02BCE57F-650C-487F-A3D5-025A480DB58AQ38201143-EE3F82CD-C3AE-48FD-A63C-41777C1A3CBAQ38741546-916D88AF-99CB-4949-B0D3-B90429BAA262Q38757938-6F4F4892-EDED-45AB-AEB9-0C474353E374Q39149556-919D3094-D138-43F2-9841-BF17A7E6C1C4Q39494833-4F1F514E-6FD5-4330-A1CB-C2E81857F2D4Q39577826-1E21E3F0-57F3-459D-ADBC-DA3B44462848Q39717742-0E53CCE0-C218-48BF-BC27-03D13787B8F1Q42209576-F0430A53-E1AB-4E3A-A9DD-28375E742AF5Q43135354-BC5AF0E0-0D2F-4722-BBF2-281207522E8FQ47147269-46B07E3D-6D60-4B7B-95B3-030F767E7A54Q50055394-1CA8EB3F-73FB-4807-8E43-CD689F171F69Q54342283-758CD978-FD80-4D0E-B78F-9CB41E100ECAQ54522930-BF949606-3FBD-4A1A-98BC-445B47C7A41A
P2860
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Constitutive JAK3 activation i ...... marrow transplantation models.
@en
Constitutive JAK3 activation i ...... marrow transplantation models.
@nl
type
label
Constitutive JAK3 activation i ...... marrow transplantation models.
@en
Constitutive JAK3 activation i ...... marrow transplantation models.
@nl
prefLabel
Constitutive JAK3 activation i ...... marrow transplantation models.
@en
Constitutive JAK3 activation i ...... marrow transplantation models.
@nl
P2093
P2860
P1433
P1476
Constitutive JAK3 activation i ...... marrow transplantation models.
@en
P2093
Benjamin H Lee
Brian Ball
D Gary Gilliland
Harvey Cantor
Jean-Philippe Merlio
Jon C Aster
Melanie G Cornejo
Michael G Kharas
Miriam B Werneck
Sandra A Moore
P2860
P304
P356
10.1182/BLOOD-2008-06-164368
P407
P577
2009-01-12T00:00:00Z